Navigation Links
Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/10/2010

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2010 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at the Lazard Capital Markets 7th Annual Healthcare Conference on Wednesday, November 17, 2010, 10:30 a.m. ET, at the St. Regis hotel in New York City.

Mr. Moch will give an update on the company's pipeline and technology assets, including CMX001, a broad-spectrum antiviral being developed for the treatment of a wide range of infections caused by double-stranded DNA (dsDNA) viruses.  CMX001 is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of dsDNA viruses, including cytomegalovirus and adenovirus.

About Chimerix and CMX001

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  

The company's lead candidate, CMX001, is in Phase 2 clinical studies in immunocompromised transplant and cancer patients for the treatment of life-threatening viruses, including cytomegalovirus and adenovirus.  Over 300 people have received CMX001 to date.  CMX001 has been well tolerated in all studies, with a growing body of evidence of the compound's antiviral activity in humans.  CMX001 has been administered to more than 200 people, including healthy volunteers and patients, in Chimerix's ongoing placebo-controlled studies.  In addition, at the request of leading physicians at over 45 medical centers throughout the United States, Canada, Europe and Israel, CMX001 has been administered to more than 100 patients under investigator-held Emergency Investigational New Drug applications (EINDs) for the treatment of a wide range of infections caused by dsDNA viruses for which there are either no approved treatments or where patients have failed the available treatment.  To date, CMX001 has been used to treat patients with 12 different dsDNA viral infections across all five families of dsDNA viruses that affect humans. CMX001 is also being developed as a medical countermeasure in the event of a smallpox release.  Chimerix has received significant funding from the National Institutes of Allergy and Infectious Disease to develop CMX001 for smallpox.  

Chimerix's second clinical-stage antiviral compound, CMX157, has completed Phase 1 clinical studies.  CMX157 is in development as a potent nucleoside analogue against multi-drug resistant HIV infections.  

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, malaria and other global public health needs.  For additional information on Chimerix, please visit http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
10. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... 2016 In response to the opioid abuse epidemic, ... for Medical Products and Tobacco, along with other FDA leaders, ... approach to opioid medications. The plan will focus on policies ... pain access to effective relief. --> ... Re-examine the risk-benefit paradigm for opioids and ensure that the ...
Breaking Medicine Technology:
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... is poised to once again host, Swirl, A Wine Tasting Event at the ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
(Date:2/5/2016)... ... 2016 , ... Boar’s Head Brand®, one of the nation’s leading providers of ... Take the stress out of your party preparation – follow these easy, yet delicious ... of the game. , “The key to hosting a successful game-day party is creating ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting held ... as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA Chairman, ... stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly served ...
Breaking Medicine News(10 mins):